Recipharm exceeds sustainability goals with major milestones

• Exceeded SBTi Scope 2 emissions reduction target (42% by 2030 on a 2021 baseline), six years ahead of schedule (48% reduction in 2024 on same baseline).
• Achieved 100% renewable electricity usage across all sites.
• Earned exceptional CDP ratings: A- in Climate and B in water, outperforming global and pharma industry CDP benchmarks.

Recipharm, a leading global pharmaceutical contract development and manufacturing organisation (CDMO), has announced major milestones in its sustainability journey, underscoring its commitment to building a more responsible pharmaceutical industry through innovation, collaboration and accountability.

In 2024, Recipharm significantly reduced its Scope 2 emissions by 48% compared to its 2021 baseline, outperforming its Science Based Targets initiative (SBTi) targets (42%) six years ahead of schedule. The company also completed its transition to 100% renewable electricity across all sites, marking a critical step towards achieving Scope 2 neutrality by 2030.

Recipharm’s improved environmental performance was also recognised externally, with upgraded scores from CDP (the Carbon Disclosure Project):

• A- in Climate Change, outperforming global and pharmaceutical sector averages.
• B in Water Security, also exceeding industry and global benchmarks.

Greg Behar, Recipharm’s CEO, said: “I am proud of the collective progress we have made in advancing our sustainability agenda. This year’s achievements reflect a significant cultural transformation, where sustainability is a shared responsibility embedded across all sites and teams, and fully integrated in our operations, innovation and growth strategy. Together, we are contributing to a more sustainable future for the pharmaceutical industry.”

These achievements reflect an organisation-wide commitment where sustainability is embedded in contracts, processes and everyday decisions, extending well beyond compliance to become a driver of long-term value.

At the heart of Recipharm’s strategy is the belief that environmental leadership must go hand in hand with innovation. The company collaborates closely with customers to advance sustainability across the value chain, from co-developing lower-impact products to optimising production processes and minimising the use of environmentally hazardous substances.

This is supported by targeted investment in sustainable infrastructure and initiatives focused on reducing energy use, waste and critical solvent dependency, reinforcing Recipharm’s long-term vision to achieve net-zero emissions by 2050.

Recipharm’s sustainability strategy is built on three core pillars:

• Environmental leadership: embedding green practices into product development, manufacturing and operations.
• Social responsibility: promoting safety, diversity and ethics across the workforce and supply chain.
• Strong governance: ensuring transparency, integrity and compliance through a robust ESG framework.

The company’s alignment with the UN Global Compact and commitment to best-in-class ESG reporting ensures that Recipharm remains ahead of evolving stakeholder and regulatory expectations.

As a trusted partner to leading pharmaceutical companies worldwide, Recipharm is proud to help shape a more sustainable industry while delivering commercial value and operational resilience.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its  ReciBioPharm division works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US and is headquartered in Stockholm, Sweden.

For more information on Recipharm, please visit www.recipharm.com and www.recibiopharm.com

Media contact:
Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708